Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728783 | 0.83 | JAK2 (0.56) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL1122640 | 0.83 | JAK2 (0.56) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL19054940 | 0.83 | MAPT (0.43) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL14294323 | 0.82 | NPC1 (0.52) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11964359 | 0.82 | NPC1 (0.43) | MAPTJAK2JAK1TYK2JAK3 | |
| SCHEMBL2762187 | 0.78 | MAPT (0.55) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL16926556 | 0.77 | JAK2 (0.58) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL1437559 | 0.76 | NR3C2 (0.54) | MAPTGSK3AMAPK10RIOK2NPSR1 | |
| SCHEMBL2759458 | 0.75 | EGFR (0.42) | MAPTFGFR4JAK2JAK1TYK2 | |
| SCHEMBL22408359 | 0.75 | FGFR4 (0.57) | MAPTGSK3AMAPK10RIOK2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | MAPT 2154/4885GSK3A 405/4885MAPK10 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.